Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Agenus Inc.
  6. Company
    AGEN   US00847G7051

AGENUS INC.

(AGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Agenus Inc.
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Number of employees : 359 people.
Sales per Business
2020
Non-cash Royalties and Milestones47.5553.9%
License Fees and Milestones22.8625.9%
Deferred Research and Development12.3014%
Other services4.625.2%
Research and Development0.750.9%
Deferred Grant0.090.1%
USD in Million
Sales per region
20192020Delta
United States149.3699.5%83.5594.8% -44.06%
Rest of World0.690.5%4.625.2% +569.42%
USD in Million
Managers
Name Title Age Since
Garo H. Armen, Dr. Chairman & Chief Executive Officer 67 2019
Jennifer S. Buell, Dr. President & Chief Operating Officer 46 2019
Christine M. Klaskin Chief Financial & Accounting Officer, VP-Finance 54 2019
Marc van Dijk, Dr. Chief Technology Officer 57 2020
Steven OĺDay, Dr. Chief Medical Officer 59 2020
Wadih Jordan Independent Director 85 2003
Brian J. Corvese Independent Director 63 2007
Ulf Arne Wiinberg Independent Director 61 2016
Timothy R. Wright Lead Independent Director 62 2009
Allison M. Jeynes-Ellis, Dr. Independent Director 54 2018
Members of the board
Name Title Age Since
Garo H. Armen, Dr. Chairman & Chief Executive Officer 67 2019
Wadih Jordan Independent Director 85 2003
Brian J. Corvese Independent Director 63 2007
Ulf Arne Wiinberg Independent Director 61 2016
Timothy R. Wright Lead Independent Director 62 2009
Allison M. Jeynes-Ellis, Dr. Independent Director 54 2018
Susan B. Hirsch Independent Director 67 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 233,114,645 203,276,093 87.2% 0 0.0% 87.2%
Stock B 0 31,620 0 0.0% 0 0.0%
Stock C 0 8,459 0 0.0% 0 0.0%
Shareholders
NameEquities%
Incyte Corporation 14,062,227 6.03%
The Vanguard Group, Inc. 13,371,107 5.74%
RTW Investments LP 11,437,238 4.91%
Gilead Sciences, Inc. 11,111,111 4.77%
SSgA Funds Management, Inc. 11,016,834 4.73%
Oracle Investment Management, Inc. 9,173,582 3.94%
Invus Public Equities Advisors LLC 6,000,000 2.57%
BlackRock Fund Advisors 5,705,683 2.45%
Millennium Management LLC 5,636,579 2.42%
Cormorant Asset Management LP 4,807,557 2.06%
Company contact information
Agenus, Inc.
3 Forbes Road
Lexington, MA 02421-7305

Phone : +1.781.674.4400
Fax : +1.781.674.4200
Web : http://www.agenusbio.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Agenus Inc.
Sector Other Biotechnology & Medical Research